- Login
- Register
- Home/Current Issue
- About the journal
- Editorial board
- Online submission
- Instructions for authors
- Subscriptions
- Foundation Acta Endocrinologica
- Archive
- Contact
Romanian Academy
The Publishing House of the Romanian Academy
ACTA ENDOCRINOLOGICA (BUC)
The International Journal of Romanian Society of Endocrinology / Registered in 1938in Web of Science Master Journal List
Acta Endocrinologica(Bucharest) is live in PubMed Central
Journal Impact Factor - click here.
This Article
Services
Google Scholar
PubMed
Acta Endocrinologica (Buc)
Jiang X, Hu H, Fu Z, Su Y, Long J
Association between the CTLA-4 EXON 1+49A/G Polymorphism and the Relapse of Grave’s Disease after ATD Withdrawal: A Meta-Analysis
Acta Endo (Buc) 2022, 18 (3): 324-332doi: 10.4183/aeb.2022.324
Background. The cytotoxic T lymphocyteassociated
molecules-4 (CTLA-4) is related to the relapse
of Graves’ disease (GD) after anti-thyroid drugs (ATDs)
withdrawal. We performed a meta-analysis to generate
large-scale evidence on whether the CTLA-4 exon 1+49A/G
polymorphism can predict the relapse of GD after ATDs
withdrawal.
Methods and Results. The PubMed, EMBASE,the
Cochrane Library and reference lists of relevant studies were
searched to identify eligible studies from inception to Jan,
2021. Ten eligible studies consisting of 1450 GD patients
with a total of 848 relapsed patients were included in the
meta-analysis.
In Caucasians patients, the CTLA-4 exon 1+49A/G
polymorphism significantly elevated the relapse risk of GD in
additive (OR = 2.07, 95% CI: 1.18-3.62, P=0.011), dominant
(OR = 2.52, 95% CI: 1.17-5.41, P=0.02), homozygote
model(OR = 3.264, 95% CI: 1.25-8.52, P=0.016), except
recessive (OR = 2.18, 95% CI = 0.98-4.86, P = 0.062) and
heterozygote model (OR = 2.141, 95% CI = 0.958-4.786,
P = 0.064). In Asian subgroup, none of these genotypes
show any associations with the relapse of GD after ATDs
withdrawal.
Conclusion. This meta-analysis suggests that the
CTLA-4 exon1 +49A/G polymorphism is associated with
the relapse risk of GD after ATDs withdrawal in Caucasians,
not Asians. Compared with the AA genotype, Caucasian
patients with GG genotype have 3.264 times risk of relapse.
A more aggressive treatment such as radioactive iodine or
thyroidectomy, or longer periods treatment of ATDs should
be recommended in Caucasian patients with the GG genotype.
Keywords: Graves’ disease, anti-thyroid drugs,
relapse, CTLA-4.
Correspondence: Jian Long, The First Affiliated Hospital of Chongqing Medical University, Department of Endocrinology, Chongqing,
China, E-mail:pudding1977@163.com